Pharmc to fund two new medicines
✎ Edit Post
Posted December 05, 2019
PHARMAC has today announced that it has approved two new medicines for funding – fulvestrant for breast cancer and olaparib for ovarian cancer, which will be funded from February 2020.
This follows earlier decisions on advanced lung cancer treatment alectinib, kadycla for advanced breast cancer and venetoclax for chronic lymphocytic leukaemia.
Five new cancer medicines have now been funded this year.